BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33078652)

  • 21. A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.
    De Marco D; Clementi N; Mancini N; Solforosi L; Moreno GJ; Sun X; Tumpey TM; Gubareva LV; Mishin V; Clementi M; Burioni R
    PLoS One; 2012; 7(4):e34415. PubMed ID: 22496802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A candidate vaccine against influenza virus intensively improved the immunogenicity of a neutralizing epitope.
    Lu Y; Ding J; Liu W; Chen YH
    Int Arch Allergy Immunol; 2002 Mar; 127(3):245-50. PubMed ID: 11979050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An amphiphilic invertible polymer as a delivery vehicle for a M2e-HA2-HA1 peptide vaccine against an Influenza A virus in pigs.
    Singh G; Zholobko O; Pillatzki A; Webb B; Nelson E; Voronov A; Ramamoorthy S
    Vaccine; 2019 Jul; 37(31):4291-4301. PubMed ID: 31235376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions.
    Mittal N; Sengupta N; Malladi SK; Reddy P; Bhat M; Rajmani RS; Sedeyn K; Saelens X; Dutta S; Varadarajan R
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Flynn JA; Weber T; Cejas PJ; Cox KS; Touch S; Austin LA; Ou Y; Citron MP; Luo B; Gindy ME; Bahl K; Ciaramella G; Espeseth AS; Zhang L
    Vaccine; 2022 Jul; 40(32):4412-4423. PubMed ID: 35680500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice.
    Son S; Ahn SB; Kim G; Jang Y; Ko C; Kim M; Kim SJ
    Antiviral Res; 2023 May; 213():105591. PubMed ID: 37003306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
    Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.
    Yoshida R; Igarashi M; Ozaki H; Kishida N; Tomabechi D; Kida H; Ito K; Takada A
    PLoS Pathog; 2009 Mar; 5(3):e1000350. PubMed ID: 19300497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Pan-H1 Influenza Vaccine.
    Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/H1 subtype hemagglutinin combined with MHC class II-restricted epitopes.
    Tan L; Lu H; Zhang D; Tian M; Hu B; Wang Z; Jin N
    Virol J; 2010 Dec; 7():363. PubMed ID: 21134292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
    Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
    J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
    Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
    J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mRNA vaccines encoding computationally optimized hemagglutinin elicit protective antibodies against future antigenically drifted H1N1 and H3N2 influenza viruses isolated between 2018-2020.
    Allen JD; Ross TM
    Front Immunol; 2024; 15():1334670. PubMed ID: 38533508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadly Reactive H2 Hemagglutinin Vaccines Elicit Cross-Reactive Antibodies in Ferrets Preimmune to Seasonal Influenza A Viruses.
    Reneer ZB; Skarlupka AL; Jamieson PJ; Ross TM
    mSphere; 2021 Mar; 6(2):. PubMed ID: 33692193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
    Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
    Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
    Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses.
    Moin SM; Boyington JC; Boyoglu-Barnum S; Gillespie RA; Cerutti G; Cheung CS; Cagigi A; Gallagher JR; Brand J; Prabhakaran M; Tsybovsky Y; Stephens T; Fisher BE; Creanga A; Ataca S; Rawi R; Corbett KS; Crank MC; Karlsson Hedestam GB; Gorman J; McDermott AB; Harris AK; Zhou T; Kwong PD; Shapiro L; Mascola JR; Graham BS; Kanekiyo M
    Immunity; 2022 Dec; 55(12):2405-2418.e7. PubMed ID: 36356572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody.
    Wyrzucki A; Dreyfus C; Kohler I; Steck M; Wilson IA; Hangartner L
    J Virol; 2014 Jun; 88(12):7083-92. PubMed ID: 24719426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.
    Zost SJ; Wu NC; Hensley SE; Wilson IA
    J Infect Dis; 2019 Apr; 219(Suppl_1):S38-S45. PubMed ID: 30535315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus.
    Huang J; Huang N; Fan M; Zhao L; Luo Y; Ding P; Tian M; Liu Q; Guo Y; Zhao J; Zheng Y; Zhang H; Ping J
    Virol J; 2020 Dec; 17(1):191. PubMed ID: 33287849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.